Engineering nanoplatforms of bacterial outer membrane vesicles to overcome cancer therapy resistance
Drug Resistance Updates · 2025-11 · 83 · 101277
DOI: 10.1016/j.drup.2025.101277 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2025-11. Verfasst von Qing-Qing Chai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Huadong Hospital, Fudan University, Shanghai, 200040, China; Department of Pharmacy, Fudan University Shanghai Cancer Center,…. Hauptthemen laut MEDLINE: Neoplasms, Drug Resistance, Neoplasm, Bacterial Outer Membrane, Antineoplastic Agents. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Key Technologies Research and Development Program, National Natural Science Foundation of China, Shanghai Key Laboratory of Clinical Geriatric Medicine.
Abstract (Originalsprache)
Resistance to cancer therapy is driven by physical barriers, tumor heterogeneity, selective therapeutic pressure, immunosuppressive tumor microenvironment (TME) and others. Bacterial outer membrane vesicles (OMVs) represent a promising nanotherapeutic platform to combat cancer therapy resistance. This review discusses the dual roles of OMVs in tumorigenesis and cancer therapy, highlighting their potential applications to enhance treatment efficacy. OMVs from pathogenic bacteria, such as Fusobacterium nucleatum and Helicobacter pylori, exacerbate chemoresistance by reshaping TME through hypoxia-induced metabolic reprogramming and immune evasion, while OMVs from some bacteria, such as probiotics, counteract immunosuppression by promoting cytotoxic T-cell infiltration and macrophage polarization. As bio-derived and conveniently engineered drug delivery platforms, OMVs maximize the synergetic anticancer effect by pathogen associated molecular patterns and the payloads. These functional payloads include siRNAs, cytotoxicity and molecular agents, and immune checkpoint inhibitors. Bacterial OMVs demonstrate unique advantages through their capacity to penetrate physical barriers, achieve tumor-specific targeting, activate immune responses, to overcome cancer therapy resistance. A successful example is the OMV-based nanoplatform with engineered OMVs co-delivering CD47-siRNA and doxorubicin to overcome drug resistance by inducing immunogenic cell death and dendritic cell activation of glioblastoma. Furthermore, OMV-based cancer vaccines presented with tumor antigens or hybridized with tumor-derived membranes enhance dendritic cell maturation and antigen-specific T-cell responses, reversing treatment resistance. By addressing challenges in mass production and safety concerns, OMVs-based platforms can be developed as powerful tools for more effective and personalized cancer treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Huadong Hospital, Fudan University, Shanghai, 200040, China; Department of Pharmacy, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China; Department of Oncology, Sh…
- Department of Pharmacy, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China; State Key Laborato…
- Department of Pharmacy, Huadong Hospital, Fudan University, Shanghai, 200040, China; Shanghai Institute of Geriatric and Gerontology, Shanghai, 200040, China; Shanghai Key Laboratory of Clinical Geriatric Medicine, Shan…
- State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, 210000, China; Shanghai Wei Er Lab, Shanghai, 201799, China. Electronic address: wuxin007@126.com.
- Department of Pharmacy, Huadong Hospital, Fudan University, Shanghai, 200040, China; State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, 210000, China; Shanghai Institute of Geriatric and Gerontolo…
Förderung
- Key Technologies Research and Development Program
- National Natural Science Foundation of China
- Shanghai Key Laboratory of Clinical Geriatric Medicine
- National Key Research and Development Program of China
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Chai, Q. Q., Li, D., Zhang, M., Gu, Y. W., Li, A. X., Wu, X., Liu, X. Y., & Liu, J. Y. (2025). Engineering nanoplatforms of bacterial outer membrane vesicles to overcome cancer therapy resistance. Drug Resistance Updates, 83, 101277. https://doi.org/10.1016/j.drup.2025.101277
Vancouver
Chai QQ, Li D, Zhang M, Gu YW, Li AX, Wu X, et al. Engineering nanoplatforms of bacterial outer membrane vesicles to overcome cancer therapy resistance. Drug Resistance Updates. 2025;83:101277. doi:10.1016/j.drup.2025.101277
BibTeX
@article{Chai2025,
author = {Chai, Qing-Qing and Li, Dan and Zhang, Min and Gu, Yong-Wei and Li, Ai-Xue and Wu, Xin and Liu, Xiao-Yan and Liu, Ji-Yong},
title = {Engineering nanoplatforms of bacterial outer membrane vesicles to overcome cancer therapy resistance},
journal = {Drug Resistance Updates},
year = {2025},
volume = {83},
pages = {101277},
doi = {10.1016/j.drup.2025.101277}
}
EUVIMED